Member Info for CaptainArchmage

BB - The IP ownership is set by the title deed, and also by other agreements, one of which has been signed in 2020 transferring the IP over to TSP and that particular agreement was fulfilled and the change lodged recently in 2023, as per the RNS. Anyways hope you managed to get in at a good price.

In the meantime, no outstanding contracts dated after that appear to have reversed this. The ownership lies with TSP.

If one were to claim they own a property where the title deed is in another's name, and cannot produce a contract that signs over the property, is that automatically considered "contested"? No? Then why is it any different here? However, more to that point, the signed contract lodged with the Patent Office (dated 2020) also indicates other IP has been transferred to TSP. Thus, it seems rather TSP can claim ownership of the other IP of Boehm if and when they decide to pursue it, which should be in good time.

Bunsen, obviously if you'd gotten in at 0.5p, it would have been better. I think this is still a strong buy despite that. The only potential issue I see now is if there are further FDA delays. I'm also seeing these as "buys" not "sells", maybe whoever had the sell order out decided to pull it.

It seems ridiculous to me that the matter of IP ownership was doubted, the document linked from the RNS last year from the Patent Office had the file signed by the inventor transferring the IP over, not licensing it. Not just that, but a lot of different patents, and reading it, it seems (in my view) any improvements he made or makes to those devices belong to the company too.

What's happening, in my view, is that the other investment and pension companies, as well as people involved, are positioning themselves in Truspine better or acting on the additional warrants.

My position remains Strong Buy, I think we'll still have to wait longer than expected for the FDA, but it looks in my view to be in a decent position.

Bunsen - Well hopefully you have a funded trading account if you want to buy. Just my views, I think, but can't confirm, it depends on how much you want. The trades under 500 on here seem to have closed at 0.5p, bigger ones went up to 0.6 or 0.7p when people wanted 1000s of quids worth. Seems to complete instantly, seems there's a massive a sell order going at a low rate to me.

I think at this point it's mostly in the bag, but still could take longer than expected. My view, still advantageous if it gives people time to get in, though not so great if you're expecting this to skyrocket tomorrow.

This is what blows my mind - in my view, we have a lot of disinformation about the company but since Laurence came to the company, things have been going in the right direction with the IP properly registered in the company name and the FDA submission (the actual submission, not the "pre-submission filing" which is for practice).

Likewise with Bunsen, I think this is a "screaming buy", it's more a question on when the FDA approval comes and how much you min/max your trades if the half penny is the bottom, since people seem to be picking up a tenth of a percent of the company or more in these trades at small value.

From here on we'll have to wait.

Based on the information available from RNS and generally on the FDA submission process, it looks like the company has kept the FDA updated through two requests during the technical review, and during the substantive review, and given we're in the substantive review it seems things are actually going fairly well.

IP ownership seems to be have been registered in the company's name with no other issues. While the FDA approval times is claimed to be 90 days, the actual average was 175 days in 2021, and the middle part of the curve is pretty flat. Seems like decent progress with the new leadership, which also seems to have more of a... spine. Considering the kind of device this is, I'm not surprised it's taken time.

https://www.ontogenmedtech.com/news-articles/how-long-does-510k-approval-take-2021

Overall in my opinion, TSP looks good to me.